575 related articles for article (PubMed ID: 26089183)
1. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
4. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
[TBL] [Abstract][Full Text] [Related]
5. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Walling D; Marder SR; Kane J; Fleischhacker WW; Keefe RS; Hosford DA; Dvergsten C; Segreti AC; Beaver JS; Toler SM; Jett JE; Dunbar GC
Schizophr Bull; 2016 Mar; 42(2):335-43. PubMed ID: 26071208
[TBL] [Abstract][Full Text] [Related]
9. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
Keefe RS; Davis VG; Spagnola NB; Hilt D; Dgetluck N; Ruse S; Patterson TD; Narasimhan M; Harvey PD
Eur Neuropsychopharmacol; 2015 Feb; 25(2):176-84. PubMed ID: 25028065
[TBL] [Abstract][Full Text] [Related]
10. Encenicline, an α7 Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice.
Salaga M; Blomster LV; Piechota-Polańczyk A; Zielińska M; Jacenik D; Cygankiewicz AI; Krajewska WM; Mikkelsen JD; Fichna J
J Pharmacol Exp Ther; 2016 Jan; 356(1):157-69. PubMed ID: 26462538
[TBL] [Abstract][Full Text] [Related]
11. Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.
Schuster RM; Pachas GN; Stoeckel L; Cather C; Nadal M; Mischoulon D; Schoenfeld DA; Zhang H; Ulysse C; Dodds EB; Sobolewski S; Hudziak V; Hanly A; Fava M; Evins AE
J Clin Psychopharmacol; 2018 Aug; 38(4):307-316. PubMed ID: 29912798
[TBL] [Abstract][Full Text] [Related]
12. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
14. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
15. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
Lieberman JA; Dunbar G; Segreti AC; Girgis RR; Seoane F; Beaver JS; Duan N; Hosford DA
Neuropsychopharmacology; 2013 May; 38(6):968-75. PubMed ID: 23303043
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
17. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
18. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
[TBL] [Abstract][Full Text] [Related]
19. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
[TBL] [Abstract][Full Text] [Related]
20. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
